Milestone Pharmaceuticals (NASDAQ:MIST) Lowered to “Hold” Rating by TD Cowen

TD Cowen cut shares of Milestone Pharmaceuticals (NASDAQ:MIST) from a strong-buy rating to a hold rating in a research report report published on Tuesday morning,Zacks.com reports.

Other equities research analysts also recently issued research reports about the company. HC Wainwright restated a “buy” rating and set a $25.00 target price on shares of Milestone Pharmaceuticals in a research report on Friday, March 28th. TD Securities downgraded Milestone Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday.

Milestone Pharmaceuticals Stock Performance

NASDAQ MIST opened at $0.80 on Tuesday. The firm has a market cap of $42.85 million, a P/E ratio of -0.99 and a beta of 1.83. The company has a quick ratio of 15.40, a current ratio of 15.40 and a debt-to-equity ratio of 2.18. The company’s 50 day moving average is $1.92 and its 200-day moving average is $1.82. Milestone Pharmaceuticals has a 12-month low of $0.71 and a 12-month high of $2.75.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Toronto Dominion Bank bought a new stake in Milestone Pharmaceuticals during the fourth quarter valued at $1,770,000. Cubist Systematic Strategies LLC bought a new stake in shares of Milestone Pharmaceuticals during the 4th quarter valued at about $73,000. Boxer Capital Management LLC purchased a new position in shares of Milestone Pharmaceuticals during the fourth quarter worth about $729,000. Northern Trust Corp increased its position in shares of Milestone Pharmaceuticals by 112.6% in the fourth quarter. Northern Trust Corp now owns 58,108 shares of the company’s stock worth $137,000 after purchasing an additional 30,772 shares during the last quarter. Finally, XTX Topco Ltd purchased a new stake in Milestone Pharmaceuticals in the fourth quarter valued at approximately $80,000. 86.18% of the stock is currently owned by hedge funds and other institutional investors.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.